PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7532289-6	1994	The most pronounced neurochemical effects of NPY were found in the hippocampus, where the peptide produced dose related increases in DA, DOPAC and HVA.	3,4-Dihydroxyphenylacetic Acid	137-142	neuropeptide Y	Rattus norvegicus	45-48	
8914867-4	1996	injections of NPY (20 microg) significantly increased extracellular NE (1.5-fold), DA (2.5-fold), DOPAC (2-fold) and HVA (3-fold), and did not change 5-HT or 5-HIAA levels.	3,4-Dihydroxyphenylacetic Acid	98-103	neuropeptide Y	Rattus norvegicus	14-17	
8914867-7	1996	produced similar neurochemical changes to NPY: it increased dialysate levels of NE (1.7-fold), DA (2.5-fold), DOPAC (1.6-fold) and HVA (2.2-fold) and did not change 5-HT or 5-HIAA levels.	3,4-Dihydroxyphenylacetic Acid	110-115	neuropeptide Y	Rattus norvegicus	42-45	
2297403-6	1990	The most consistent finding was a dose-related increase of both DA and DOPAC levels after treatment with NPY.	3,4-Dihydroxyphenylacetic Acid	71-76	neuropeptide Y	Rattus norvegicus	105-108	
2477116-3	1989	The concentration of serotonin and its metabolite 5-HIAA as well as DOPAC were also reduced in the ventromedial hypothalamus following local injection of NPY.	3,4-Dihydroxyphenylacetic Acid	68-73	neuropeptide Y	Rattus norvegicus	154-157	
2477116-4	1989	When NPY was injected into the lateral hypothalamus and monoamines measured from areas adjacent to the injection of NPY there was a significant increase in norepinephrine release and a significant increase in the concentration of DOPAC.	3,4-Dihydroxyphenylacetic Acid	230-235	neuropeptide Y	Rattus norvegicus	5-8	
2477116-4	1989	When NPY was injected into the lateral hypothalamus and monoamines measured from areas adjacent to the injection of NPY there was a significant increase in norepinephrine release and a significant increase in the concentration of DOPAC.	3,4-Dihydroxyphenylacetic Acid	230-235	neuropeptide Y	Rattus norvegicus	116-119	
12213136-8	2002	injection of NPY (10 microg) or orexin A (1 microg) concomitantly increased median eminence DOPAC and decreased serum prolactin concentrations.	3,4-Dihydroxyphenylacetic Acid	92-97	neuropeptide Y	Rattus norvegicus	13-16